Sign In
Buy PACB
$1.15
-0.0350 (-2.95%)
At Close: Aug 10, 2026
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up – Time to Buy?
02:27am, Sunday, 04'th Jan 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) shares gapped up before the market opened on Friday. The stock had previously closed at $1.87, but opened at $1.95. Pacific Bio
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab
06:26am, Wednesday, 31'st Dec 2025
Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while
PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 30'th Dec 2025
MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenti
TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock
12:51pm, Monday, 29'th Dec 2025
Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin
Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.1% – Should You Sell?
02:55am, Sunday, 28'th Dec 2025
Shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) dropped 5.1% during trading on Friday. The stock traded as low as $1.79 and last traded at $1.7850. Approximately 1,8
Pacific Biosciences of California Target of Unusually Large Options Trading (NASDAQ:PACB)
01:14am, Tuesday, 23'rd Dec 2025
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) was the target of some unusual options trading on Monday. Stock traders acquired 8,267 call options on the stock. This represen
PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
09:05am, Friday, 28'th Nov 2025
MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target at $2.00
02:16am, Saturday, 22'nd Nov 2025
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) has earned a consensus recommendation of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Rating
Pacific Biosciences of California (NASDAQ:PACB) Shares Cross Above 200 Day Moving Average – Here’s Why
02:58am, Wednesday, 19'th Nov 2025
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.
Top 3 Genomics Stocks to Consider for Your Portfolio
09:51am, Tuesday, 18'th Nov 2025
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
01:01pm, Thursday, 13'th Nov 2025
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y
02:21pm, Thursday, 06'th Nov 2025
PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.
Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript
09:41pm, Wednesday, 05'th Nov 2025
Pacific Biosciences of California, Inc. ( PACB ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Christian Henry - President, CEO & Director James Gibson - Chief Financial Offi
Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics
07:31pm, Wednesday, 05'th Nov 2025
Although the revenue and EPS for Pacific Biosciences (PACB) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare w
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
06:56pm, Wednesday, 05'th Nov 2025
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.17 per share a year ago
